Clinical trial
A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants Receiving Standard of Care (NEPTUNIA)
NCT05650567 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants Receiving Standard of Care (NEPTUNIA)
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 19, 2023
- Completion date
- June 25, 2025
- Enrollment
- 20 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.